mercredi 26 juin 2019

Onco Actu du 26 juin 2019


1.1 BIOLOGIE - GÉNOME



More Evidence That Most Cancer Mutations Are Simply The Result Of Bad Luck [Forbes]










2.11 ETIOLOGIE - ALIMENTATION



What the Science Really Says About Grilled Meat and Cancer Risk [Time]











3.1.1 PRÉVENTION - TABAC - E-CIGS



San Francisco Bans Sale of Juul and Other E-Cigarettes [NY Times]










San Francisco Bans Sales Of E-Cigarettes [NPR]











Juul loses home turf as San Francisco bans e-cigarette sales [Reuters]











3.4 CHIMIOPRÉVENTION



Fish oil and cancer prevention [VUMC]











4.1 DÉP., DIAG. & PRONO. - PROSTATE



Simple prostate cancer test could diagnose five years early and prevent thousands of invasive operations [The Telegraph]











Prostate cancer: New urine test hope [BBC News]











4.10 DÉP., DIAG. & PRONO. - POUMON



Lung cancer screening: Women benefit significantly [DFKZ]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Pediatric Cancer Big Data Initiatives Could Help Set Best Practices for Sequencing, Data Sharing [Genome Web]










4.9 DÉP., DIAG. & PRONO. - SEIN



AI could help radiologists improve their mammography interpretation [Stanford Medicine]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



New Drug Target Found in Subset of Metastatic Prostate Cancers [Dana-Farber Cancer Institute]











Tamp the Tumor [Harvard Medical School]










5.12 IMMUNOTHÉRAPIES



Clinical Utility of Neoadjuvant Immune Checkpoint Inhibitors in Resectable NSCLC Remains Unknown [ESMO]











5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Intensity Therapeutics Announces Clinical Collaboration with Merck [Intensity Therapeutics]











Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies [Gilead]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Immunotherapy prevents relapse in small leukemia trial [Fred Hutch]











5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



Immunotherapy and HDAC inhibition are anti-cancer besties [Colorado Cancer Blogs]











5.2 PHARMA



GSK/Tesaro PARP inhibitor Zejula wins another speedy review [EndPoints]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



AbbVie to Pay $63B for Allergan to Prepare for Life Without Humira [Xconomy]











AbbVie, nearing the end of Humira's historic run, scoops up a struggling Allergan for $63B [Fierce Pharma]










AbbVie buying Allergan in $63B deal for its post-Humira future [Biopharma Dive]











AbbVie's $63B buyout spotlights the return of major M&A deals — despite the backlash [EndPoints]











Botox Maker Allergan Is Sold to AbbVie in $63 Billion Deal [NY Times]











AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants [STAT]











5.2.3 PHARMA - ÉCONOMIE



Chris Varma unveils MPM's latest startup -- eyeing 'undruggable' cancer targets and powered by machine learning, $67M [EndPoints]











6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES



Has Google finally adjusted its algorithm to deprioritize quack content? Dr. Mercola thinks so. [Respectful Insolence]











6.6 PUBLICATIONS



Decoding team and individual impact in science and invention [PNAS]










6.7 DMP, BIG DATA & APPLIS



NICE explores extending its use of real world data to inform its guidance [NICE]











Jane Wilcock: The digitalisation of NHS patient care should be medically tested [BMJ]